Wu, Yi Hsieng SamuelYi Hsieng SamuelWuLin, Yi LingYi LingLinKao, Yi FengYi FengKaoChen, Jr WeiJr WeiChenChen, Yi ChouYi ChouChenYI-CHEN CHEN2023-12-252023-12-252024-0315204081https://www.scopus.com/record/display.uri?eid=2-s2.0-85178418508&origin=resultslisthttps://scholars.lib.ntu.edu.tw/handle/123456789/638122Tons of broiler livers are produced yearly in Taiwan but always considered waste. Our team has successfully patented and characterized a chicken-liver hydrolysate (CLH) with several biofunctions. Chronic alcohol consumption causes hepatosteatosis or even hepatitis, cirrhosis, and cancers. This study was to investigate the hepatoprotection of CLH-based supplement (GBHP01™) against chronic alcohol consumption. Results showed that GBHP01™ could reduce (p <.05) enlarged liver size, lipid accumulation/steatosis scores, and higher serum AST, ALT, γ-GT, triglyceride, and cholesterol levels induced by an alcoholic liquid diet. GBHP01™ reduced liver inflammation and apoptosis in alcoholic liquid-diet-fed mice via decreasing TBARS, interleukin-6, interleukin-1β, and tumor necrosis factor-α levels, increasing reduced GSH/TEAC levels and activities of SOD, CAT and GPx, as well as downregulating CYP2E1, BAX/BCL2, Cleaved CASPASE-9/Total CASPASE-9 and Active CASPASE-3/Pro-CASPASE-3 (p <.05). Furthermore, GBHP01™ elevated hepatic alcohol metabolism (ADH and ALDH activities) (p <.05). In conclusion, this study prove the hepatoprotection of GBHP01™ against alcohol consumption.enalcohol metabolism | anti-inflammatory response | antiapoptosis | antioxidant capacity | chicken-liver hydrolysate-based supplementjournal article10.1002/tox.24072380543882-s2.0-85178418508https://api.elsevier.com/content/abstract/scopus_id/85178418508